而依据引起肿瘤细胞PD-L1表达的分子机制,可将PD-L1表达分为组成型PD-L1表达(constitutive PD-L1 expression)和诱导型PD-L1表达(inducible PD-L1 expression)。前者一般由肿瘤相关基因的变异所致,表现为肿瘤细胞PD-L1表达呈均一分布,与免疫治疗疗效相关性不...
Keytruda NSCLC Approval Will Test PD-L1 ExpressionEmily Hayes
pathologist‑based assessment of 4 immunohistochemistry assays for PD‑L1 expression in non‑small cell lung cancer[J]. JAMA Oncol, 2017, 3(8):1051‑1058. DOI: 10.1001/jamaoncol.2017.0013.[6]Xue, Liyan et al. “Concordance between four PD-L1 immunohistochemical assays and 22C3 pharmDx ...
因此,本研究旨在使用仅手术完整切除标本的大量真实世界肺癌病例中比较两种PD-L1检测,即SP263和22C3,并评估在决定是否给予辅助阿替利珠单抗时22C3是否可以替代SP263。 研究方法 使用临床实践和临床试验中常用的阈值,将PD-L1表达<1%定义为阴性,1%-49%+定义为弱阳性,≧50%定义为强阳性。为了比较检测的临床性能,计算...
[9] Munari E, Zamboni G, Lunardi G, et al. PD-L1 expression in non-small cell lung cancer: evaluation of the diagnostic accuracy of a laboratory-developed test using clone E1L3N in comparison with 22C3 and SP263 assays. Hum Pathol. 2019;90:54-59. doi:10.1016/j.humpath.2019.05.003...
5. Phillips, T., et al., Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer. Appl Immunohistochem Mol Morphol, 2015. 23(8): p. 541-9. 6. Velcheti, V., et al., Programmed death ligand-1 expression in non-small cell lung cancer. Lab...
Most ICIs target programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) axis with the aim of restoring antitumor immunity. Multiple clinical trials for ICIs have evaluated a predictive value of PD-L1 protein expression in tumor cells and tumor-infiltrating immune cells (...
expression of PD-L1 in patients with esophageal squamous cell carcinoma (ESCC) and the consistency and correlation of IHC detection of seven different clones of PD-L1 antibody, and to provide reference for the gradual ...
Shigeta N, Murakami S, Yokose T, et al. Comparison of SP263 and 22C3 pharmDx assays to test programmed death ligand-1 (PD-L1) expression in surgically resected non-small cell lung cancer. Thorac Cancer. 2024;15(17):1343-1349. doi:10.1111/1759-7714.15319...
increased (BCCA-test-con and MA31-con), revealing the inter pathologist variability. In addition to quality assurance, the system could be used to allow pathologists to spare IHC staining and interpretation from more than 70% of the patients while retaining 100% sensitivity for PD-L1 expression ...